

Annexure I

Extract from the draft Composite Scheme of Amalgamation

PART III: Amalgamation of Symed Labs Limited ("Transferor Company 1"), Vandana Life Sciences Private Limited ("Transferor Company 2"), Appcure Labs Private Limited ("Transferor Company 3"), Vindhya Pharma (India) Private Limited ("Transferor Company 4") and S.V. Labs Private Limited ("Transferor Company 5") with Viyash Life Sciences Private Limited ("Transferee Company 1"):

17. ACCOUNTING TREATMENT

17.1 Accounting treatment in the books of the Transferee Company 1:

17.1.1. Upon Part III of the Scheme coming into effect, the Transferee Company 1 shall account for the amalgamation of the Transferor Companies, together, in its books of accounts as per the 'Pooling of Interest Method' in accordance with accounting principles as laid down in Appendix C the Indian Accounting Standard 103 (Business Combinations), notified under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as may be amended from time to time, in the books of accounts of the Transferee Company 1 such that:

- (i) the Transferee Company 1 shall record the assets, liabilities and reserves, if any, of the Transferor Companies vested in it pursuant to this Scheme, at the carrying values as appearing in the consolidated financial statements of the Transferee Company 1;
- (ii) the identity of the reserves of the Transferor Companies shall be preserved and the Transferee Company 1 shall record the reserves of the Transferor Companies in the same form and at the carrying amount as appearing in the consolidated financial statements of the Transferee Company 1 (subject to clauses mentioned below);
- (iii) the inter-company balances between the Transferor Companies and the Transferee Company 1; if any, appearing in the books of the Transferee Company 1 and / or the Transferor Companies shall stand cancelled with no further obligation in that behalf;
- (iv) the value of all the investments held by the Transferee Company 1 in the Transferor Companies shall stand cancelled;
- (v) the surplus/deficit, if any arising after taking the effect of above clauses shall be transferred to Capital Reserve / Amalgamation adjustment deficit account as the case may be, in the financial statements of the Transferee Company 1 and shall be presented separately from other capital reserves with disclosure of its nature and purpose in the notes.



Viyash Life Sciences Private Limited.

Registered Office :

Plot No. 290, Srivalli's Corporate

Road No. 6, Kakatiya Hills, Madhapur

Hyderabad - 500 081. Telangana, India

T: +91 93911 39986 | E: info@viyash.com

CIN : U24239TG2019PTC130774

- (vi) in case of any difference in accounting policy between the Transferor Companies and the Transferee Company 1, the accounting policies followed by the Transferee Company 1 will prevail to ensure that the financial statements reflect the financial position based on consistent accounting policies;
- (vii) comparative financial information in the financial statements of the Transferee Company 1 shall be restated for the accounting impact of amalgamation of the Transferor Companies, as stated above, as if the amalgamation had occurred from the beginning of the comparative period. However, if business combination had occurred after that date, the prior period information shall be restated only from that date;
- (viii) any matter not dealt with in clauses hereinabove shall be dealt with in accordance with the requirement of applicable Indian Accounting Standards.

For VIYASH LIFE SCIENCES PRIVATE LIMITED


Authorised Signatory



R&D CENTRE :
Plot No. 89/A, Phase - I
IDA, Jeedimella
Telangana-500 055. India.
T : +91 40 2363 5045

Manufacturing Unit - I :
Plot No. 1-A/2 And 1-A/3
MIDC, Industrial Area,
Taloja, Panvel, Raigarh - 410208.
Maharashtra, India. T : +91 22623 45515

Manufacturing unit - II :
Plot No. 28, Sy. No. 1,3,9 & 26, Thanam Village
Parawada Mandal, Visakhapatnam District.
Andrapradesh-531019. India.
T : +91 98481 92205